Stryker Co. (NYSE:SYK) Stock Holdings Lifted by HealthInvest Partners AB

HealthInvest Partners AB increased its holdings in shares of Stryker Co. (NYSE:SYK) by 17.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,460 shares of the medical technology company’s stock after acquiring an additional 3,477 shares during the quarter. Stryker makes up about 4.0% of HealthInvest Partners AB’s holdings, making the stock its 8th largest position. HealthInvest Partners AB’s holdings in Stryker were worth $8,475,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SYK. Charles Schwab Investment Management Inc. increased its stake in shares of Stryker by 1.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,936,226 shares of the medical technology company’s stock worth $699,481,000 after purchasing an additional 37,000 shares in the last quarter. Smithfield Trust Co lifted its position in shares of Stryker by 10.6% during the third quarter. Smithfield Trust Co now owns 1,937 shares of the medical technology company’s stock worth $694,000 after acquiring an additional 186 shares in the last quarter. Integrated Investment Consultants LLC grew its position in shares of Stryker by 11.0% in the third quarter. Integrated Investment Consultants LLC now owns 3,836 shares of the medical technology company’s stock valued at $1,386,000 after purchasing an additional 380 shares in the last quarter. German American Bancorp Inc. raised its stake in shares of Stryker by 6.6% during the 3rd quarter. German American Bancorp Inc. now owns 758 shares of the medical technology company’s stock valued at $274,000 after purchasing an additional 47 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Stryker by 4.8% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 50,506 shares of the medical technology company’s stock valued at $18,246,000 after acquiring an additional 2,322 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Up 0.2 %

Shares of NYSE:SYK traded up $0.81 during trading on Thursday, reaching $386.49. 35,481 shares of the stock traded hands, compared to its average volume of 1,265,116. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a 52-week low of $285.79 and a 52-week high of $398.20. The stock has a market cap of $147.34 billion, a P/E ratio of 41.34, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91. The stock has a 50-day moving average of $365.46 and a two-hundred day moving average of $348.66.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the company posted $2.46 EPS. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. As a group, sell-side analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Insider Transactions at Stryker

In other news, VP M Kathryn Fink sold 7,347 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. The trade was a 42.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 67,381 shares of company stock valued at $24,825,275 over the last 90 days. Company insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on SYK shares. BTIG Research boosted their price target on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. upped their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Evercore ISI lifted their price target on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Wells Fargo & Company increased their price objective on Stryker from $381.00 to $405.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Finally, Royal Bank of Canada boosted their target price on Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.